ImmunoGen (IMGN) News Today → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free imgn Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 25, 2024 | seekingalpha.comPolaris Global Equity Composite Q1 2024 CommentaryApril 25, 2024 | investing.comLazard posts first-quarter profit on deals, assets boostApril 23, 2024 | seekingalpha.com3 Potential Biopharma Buyout TargetsMarch 22, 2024 | marketwatch.comAbbVie Gets Full OK For Cancer Drug Acquired in ImmunoGen DealMarch 1, 2024 | marketbeat.comFred Alger Management LLC Purchases 316,201 Shares of ImmunoGen, Inc. (NASDAQ:IMGN)Fred Alger Management LLC lifted its position in shares of ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) by 817.9% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 354,859 shares of the biotechnology company's stock after buyFebruary 28, 2024 | marketbeat.comFmr LLC Has $91.86 Million Position in ImmunoGen, Inc. (NASDAQ:IMGN)Fmr LLC raised its holdings in ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) by 3.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,788,555 shares of the biotechnology company's stock after buying an additional 175,813 sFebruary 21, 2024 | msn.comAbbVie plans to offer senior notes to fund Immunogen, Cerevel dealsFebruary 19, 2024 | ca.finance.yahoo.comCERE Aug 2024 30.000 callFebruary 18, 2024 | marketbeat.comRafferty Asset Management LLC Acquires 229,699 Shares of ImmunoGen, Inc. (NASDAQ:IMGN)Rafferty Asset Management LLC boosted its position in ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) by 68.1% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 566,985 shares of the biotechnology company's stock after purchasing an additional 229February 17, 2024 | marketbeat.comState of New Jersey Common Pension Fund D Cuts Stock Position in ImmunoGen, Inc. (NASDAQ:IMGN)State of New Jersey Common Pension Fund D lessened its position in shares of ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) by 10.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 156,835 shares of the biotechnology company'sFebruary 16, 2024 | marketbeat.comSkandinaviska Enskilda Banken AB publ Invests $769,000 in ImmunoGen, Inc. (NASDAQ:IMGN)Skandinaviska Enskilda Banken AB publ acquired a new position in shares of ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 48,515 shares of the biotechnoloFebruary 12, 2024 | marketbeat.comRhenman & Partners Asset Management AB Sells 571,716 Shares of ImmunoGen, Inc. (NASDAQ:IMGN)Rhenman & Partners Asset Management AB lowered its holdings in shares of ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) by 76.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 178,284 shares of theFebruary 12, 2024 | markets.businessinsider.comBarclays Keeps Their Hold Rating on ImmunoGen (IMGN)February 12, 2024 | msn.comAbbVie revises Q1 earnings outlook as ImmunoGen deal closesFebruary 12, 2024 | marketbeat.comTrading was temporarily halted for "IMGN" at 07:02 PM with a stated reason of "News pending."February 10, 2024 | marketbeat.comBarclays PLC Boosts Stake in ImmunoGen, Inc. (NASDAQ:IMGN)Barclays PLC grew its holdings in ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) by 28.6% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 342,727 shares of the biotechnology company's stock after acquiring an additional 76,185 shares during theFebruary 9, 2024 | marketbeat.comImmunoGen (NASDAQ:IMGN) Sees Strong Trading VolumeImmunoGen (NASDAQ:IMGN) Sees Unusually-High Trading VolumeFebruary 9, 2024 | finance.yahoo.comIs ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?February 9, 2024 | seekingalpha.comFinal Countdown: AbbVie's Imminent Closure With ImmunoGen And What It MeansFebruary 9, 2024 | msn.comImmunoGen Set to Merge with AbbVie, Awaiting Final ApprovalFebruary 9, 2024 | finance.yahoo.comImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?February 8, 2024 | marketbeat.comImmunoGen (NASDAQ:IMGN) Hits New 52-Week High at $31.24ImmunoGen (NASDAQ:IMGN) Reaches New 1-Year High at $31.24February 3, 2024 | marketbeat.comJump Financial LLC Lowers Holdings in ImmunoGen, Inc. (NASDAQ:IMGN)Jump Financial LLC trimmed its holdings in ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) by 56.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 113,128 shares of the biotechnology company's stockFebruary 2, 2024 | marketbeat.comMoody Aldrich Partners LLC Has $4.51 Million Stock Holdings in ImmunoGen, Inc. (NASDAQ:IMGN)Moody Aldrich Partners LLC raised its stake in ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) by 38.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 283,950 shares of the biotechnology company's stock after buying an additional 79,094 shareFebruary 2, 2024 | finance.yahoo.comImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 2, 2024 | marketbeat.comBrokers Set Expectations for ImmunoGen, Inc.'s Q4 2024 Earnings (NASDAQ:IMGN)ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) - Zacks Research lowered their Q4 2024 earnings per share (EPS) estimates for ImmunoGen in a research report issued on Wednesday, January 31st. Zacks Research analyst K. Das now expects that the biotechnology company will post earnings per share of $0.1February 2, 2024 | finance.yahoo.comImmunoGen, Inc. (IMGN) Interactive Stock Chart - Yahoo FinanceFebruary 1, 2024 | marketbeat.comFY2023 Earnings Estimate for ImmunoGen, Inc. (NASDAQ:IMGN) Issued By Zacks ResearchImmunoGen, Inc. (NASDAQ:IMGN - Free Report) - Zacks Research upped their FY2023 earnings per share (EPS) estimates for shares of ImmunoGen in a report issued on Wednesday, January 31st. Zacks Research analyst K. Das now forecasts that the biotechnology company will post earnings of $0.03 per sharJanuary 31, 2024 | marketbeat.comAlpha DNA Investment Management LLC Purchases New Shares in ImmunoGen, Inc. (NASDAQ:IMGN)Alpha DNA Investment Management LLC purchased a new stake in shares of ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 35,896 shares of the biotechnology company's stock, vJanuary 23, 2024 | marketbeat.comRaymond James & Associates Buys 150,652 Shares of ImmunoGen, Inc. (NASDAQ:IMGN)Raymond James & Associates raised its holdings in ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) by 890.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 167,578 shares of the biotechnology company's stock after buying an additioJanuary 21, 2024 | marketbeat.comStrs Ohio Reduces Stake in ImmunoGen, Inc. (NASDAQ:IMGN)Strs Ohio reduced its stake in ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) by 62.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,000 shares of the biotechnology company's stock after sellinJanuary 20, 2024 | marketbeat.comLord Abbett & CO. LLC Reduces Stock Holdings in ImmunoGen, Inc. (NASDAQ:IMGN)Lord Abbett & CO. LLC reduced its stake in shares of ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) by 17.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 759,450 shares of the biotechnology company's stock after selling 159,545 shares duriJanuary 19, 2024 | marketbeat.comBank of New York Mellon Corp Boosts Stock Position in ImmunoGen, Inc. (NASDAQ:IMGN)Bank of New York Mellon Corp lifted its position in shares of ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) by 64.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,796,110 shares of the biotechnology company'sJanuary 18, 2024 | marketbeat.comInsider Selling: ImmunoGen, Inc. (NASDAQ:IMGN) SVP Sells 187,667 Shares of StockImmunoGen, Inc. (NASDAQ:IMGN - Get Free Report) SVP Theresa Wingrove sold 187,667 shares of the company's stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $29.64, for a total value of $5,562,449.88. Following the completion of the sale, the senior vice president now owns 3,426 shares in the company, valued at approximately $101,546.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.January 18, 2024 | marketbeat.comTD Asset Management Inc Purchases 184,500 Shares of ImmunoGen, Inc. (NASDAQ:IMGN)TD Asset Management Inc increased its position in ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) by 188.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 282,400 shares of the biotechnologyJanuary 15, 2024 | marketbeat.comImmunoGen, Inc. (NASDAQ:IMGN) Sees Significant Increase in Short InterestImmunoGen, Inc. (NASDAQ:IMGN - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 20,640,000 shares, a growth of 5.6% from the December 15th total of 19,550,000 shares. Based on an average trading volume of 8,050,000 shares, the days-to-cover ratio is presently 2.6 days.January 9, 2024 | marketbeat.comEmerald Mutual Fund Advisers Trust Has $23.27 Million Holdings in ImmunoGen, Inc. (NASDAQ:IMGN)Emerald Mutual Fund Advisers Trust raised its holdings in shares of ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) by 79.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,466,063 shares of the biotechnologyJanuary 9, 2024 | finance.yahoo.comHow ImmunoGen (IMGN) Stock Stands Out in a Strong IndustryJanuary 8, 2024 | marketbeat.comEmerald Advisers LLC Purchases 827,609 Shares of ImmunoGen, Inc. (NASDAQ:IMGN)Emerald Advisers LLC grew its position in ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) by 84.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,811,306 shares of the biotechnology company's stock after buying an additional 827January 8, 2024 | marketbeat.comImmunoGen, Inc. (NASDAQ:IMGN) Receives Average Rating of "Hold" from BrokeragesShares of ImmunoGen, Inc. (NASDAQ:IMGN - Get Free Report) have earned a consensus rating of "Hold" from the twelve analysts that are covering the company, MarketBeat reports. Nine research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The avJanuary 4, 2024 | nasdaq.comIMGN Quantitative Stock AnalysisJanuary 4, 2024 | msn.comAll You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong BuyJanuary 4, 2024 | marketbeat.comFY2023 EPS Estimates for ImmunoGen, Inc. Raised by Analyst (NASDAQ:IMGN)ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) - Research analysts at Zacks Research boosted their FY2023 earnings per share (EPS) estimates for shares of ImmunoGen in a research note issued to investors on Tuesday, January 2nd. Zacks Research analyst K. Das now expects that the biotechnology companJanuary 3, 2024 | marketbeat.comQ4 2023 Earnings Estimate for ImmunoGen, Inc. (NASDAQ:IMGN) Issued By Zacks ResearchImmunoGen, Inc. (NASDAQ:IMGN - Free Report) - Zacks Research upped their Q4 2023 earnings per share (EPS) estimates for shares of ImmunoGen in a research note issued on Tuesday, January 2nd. Zacks Research analyst K. Das now expects that the biotechnology company will post earnings per share of $January 1, 2024 | marketbeat.comImmunoGen, Inc. (NASDAQ:IMGN) Stake Trimmed by Pinnacle Associates Ltd.Pinnacle Associates Ltd. lowered its stake in ImmunoGen, Inc. (NASDAQ:IMGN - Free Report) by 16.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,016,156 shares of the biotechnology company's stock aDecember 31, 2023 | marketbeat.comImmunoGen, Inc. (NASDAQ:IMGN) Short Interest Down 48.7% in DecemberImmunoGen, Inc. (NASDAQ:IMGN - Get Free Report) was the recipient of a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 19,550,000 shares, a decrease of 48.7% from the November 30th total of 38,120,000 shares. Based on an average trading volume of 7,595,700 shares, the short-interest ratio is currently 2.6 days.December 27, 2023 | marketbeat.comInsider Selling: ImmunoGen, Inc. (NASDAQ:IMGN) VP Sells 6,548 Shares of StockImmunoGen, Inc. (NASDAQ:IMGN - Get Free Report) VP Renee Lentini sold 6,548 shares of ImmunoGen stock in a transaction on Tuesday, December 26th. The stock was sold at an average price of $29.74, for a total value of $194,737.52. Following the transaction, the vice president now directly owns 8,452 shares of the company's stock, valued at approximately $251,362.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.December 27, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EAR, IMGN, CVLYDecember 22, 2023 | finance.yahoo.comAre Investors Undervaluing ImmunoGen, Inc. (NASDAQ:IMGN) By 38%?December 19, 2023 | marketbeat.comImmunoGen, Inc. (NASDAQ:IMGN) SVP Sells $3,452,883.00 in StockImmunoGen, Inc. (NASDAQ:IMGN - Get Free Report) SVP Theresa Wingrove sold 117,445 shares of the firm's stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $29.40, for a total value of $3,452,883.00. Following the sale, the senior vice president now directly owns 2,811 shares in the company, valued at $82,643.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Get ImmunoGen News Delivered to You Automatically Sign up to receive the latest news and ratings for IMGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Write this ticker symbol down… (Ad)A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything. Discover the #1 company leading this revolution IMGN Media Mentions By Week IMGN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMGN News Sentiment▼0.000.77▲Average Medical News Sentiment IMGN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMGN Articles This Week▼04▲IMGN Articles Average Week Get ImmunoGen News Delivered to You Automatically Sign up to receive the latest news and ratings for IMGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RYTM News Today SUPN News Today KNSA News Today ARQT News Today OCUL News Today PLRX News Today PHAT News Today TBPH News Today BIIB News Today ALNY News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMGN) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldAlert: Your Bank is Dying – Act Now or Lose Everything!Priority GoldNext President (Not Trump. Not Biden.)The Freeport SocietyWrite this ticker symbol down…StocksToTradeTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHistoric Crash Could Wipe Away Your 401k (Govt Debt Explosion)Birch GoldPrepare for a Recession Unlike Any OtherAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
